SRPT Sarepta Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SRPT

Price (delayed)

$84.44

Market cap

$7.9B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.83

Enterprise value

$8.73B

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights
The company's equity has surged by 77% YoY and by 3.1% QoQ
SRPT's gross profit is up by 32% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.sarepta.com/
Peers: GILD NVAX PTCT BCRX

Key stats

What are the main financial stats of SRPT
Market
Shares outstanding
93.55M
Market cap
$7.9B
Enterprise value
$8.73B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.3
Price to sales (P/S)
6.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.9
Earnings
Revenue
$1.1B
EBIT
-$661.78M
EBITDA
-$604.01M
Free cash flow
-$603.76M
Per share
EPS
-$7.83
Free cash flow per share
-$6.79
Book value per share
$8.19
Revenue per share
$12.43
TBVPS
$34.98
Balance sheet
Total assets
$3.11B
Total liabilities
$2.35B
Debt
$1.37B
Equity
$764.36M
Working capital
$2B
Liquidity
Debt to equity
1.79
Current ratio
5.44
Quick ratio
4.55
Net debt/EBITDA
-1.37
Margins
EBITDA margin
-54.7%
Gross margin
87.6%
Net margin
-62.5%
Operating margin
-36.1%
Efficiency
Return on assets
-22.2%
Return on equity
-106.1%
Return on invested capital
-20.8%
Return on capital employed
-24.9%
Return on sales
-59.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
3.89%
1 week
1.89%
1 month
10.35%
1 year
-31.34%
YTD
-34.84%
QTD
-30.34%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$1.1B
Gross profit
$968.02M
Operating income
-$399.28M
Net income
-$690.88M
Gross margin
87.6%
Net margin
-62.5%
SRPT's operating margin is up by 41% YoY and by 29% from the previous quarter
SRPT's gross profit is up by 32% year-on-year and by 12% since the previous quarter
SRPT's net margin is up by 31% since the previous quarter and by 24% year-on-year
The revenue rose by 26% YoY and by 10% QoQ

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
10.3
P/S
6.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.9
The EPS has grown by 24% from the previous quarter and by 4.7% YoY
The company's equity has surged by 77% YoY and by 3.1% QoQ
SRPT's P/B is 46% below its last 4 quarters average of 18.9 and 18% below its 5-year quarterly average of 12.6
The P/S is 59% less than the 5-year quarterly average of 16.6 and 39% less than the last 4 quarters average of 11.1
The revenue rose by 26% YoY and by 10% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The return on equity is up by 34% since the previous quarter but it has declined by 9% year-on-year
The ROS has grown by 32% from the previous quarter and by 26% YoY
Sarepta Therapeutics's ROIC has increased by 28% from the previous quarter and by 27% YoY
The ROA has increased by 24% from the previous quarter and by 4.3% YoY

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 33% more than the total liabilities
The company's current ratio rose by 25% YoY and by 10% QoQ
Sarepta Therapeutics's quick ratio has increased by 21% YoY and by 8% from the previous quarter
SRPT's debt is 79% greater than its equity
The company's equity has surged by 77% YoY and by 3.1% QoQ
The debt to equity has dropped by 51% year-on-year and by 2.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.